# Olio Labs **Source:** https://geo.sig.ai/brands/olio-labs **Vertical:** Healthcare **Subcategory:** General **Tier:** Emerging **Website:** oliolabs.co **Last Updated:** 2026-04-14 ## Summary SF AI drug discovery company identifying multi-protein combination therapeutics 4x faster at 90% lower cost; YC S23 $4.5M Boom Capital Series A with in vivo/vitro results competing with Recursion for combination therapy AI. ## Company Overview Olio Labs is a San Francisco-based computational drug discovery company using AI and machine learning to identify multi-protein combination therapeutics for complex diseases — targeting biological pathways where single-target drugs fail because the disease involves multiple protein interactions simultaneously. Founded in 2023 and backed by Y Combinator (S23) with $5 million raised including a $4.5 million Series A led by Boom Capital and Overwater Ventures in March 2025, Olio Labs' combination therapeutics platform has demonstrated in vivo and in vitro superiority over existing market drugs, with a discovery process claimed to be 4x faster and 90% lower cost than traditional drug development approaches. Olio Labs' multi-protein targeting approach addresses a fundamental limitation in drug development: most diseases — particularly cancer, autoimmune disorders, and neurological conditions — are driven by dysregulation across multiple protein pathways simultaneously. Single-target drugs (kinase inhibitors, checkpoint inhibitors) achieve partial response but face resistance as tumor cells activate compensatory pathways. Olio Labs' AI platform models protein interaction networks to identify combination therapies — selecting multiple agents that simultaneously target complementary pathway vulnerabilities — predicting synergistic drug combinations that human researchers cannot systematically explore across the combinatorial space of available compounds. In 2025, Olio Labs competes in the AI drug discovery and combination therapeutics market with Recursion Pharmaceuticals (NASDAQ: RXRX, large-scale phenomics and ML drug discovery), Insilico Medicine (AI generative drug design), and Relay Therapeutics (NASDAQ: RLAY, protein motion-based drug design) for AI-powered drug discovery positioning. The combination therapeutics field has validated market analogs — Pfizer's KRAS G12C inhibitor combination trials and cancer immunotherapy combinations have demonstrated that multi-agent oncology regimens outperform monotherapy. Olio Labs' YC-backing places it in the computational biotech community intersecting AI and drug discovery. The 2025 strategy focuses on identifying lead combination candidates for clinical development partnerships with pharmaceutical companies, generating additional preclinical proof-of-concept data, and raising Series B funding to advance the most promising combinations into IND-enabling studies. ## Frequently Asked Questions ### What is Olio Labs? Olio Labs is a healthcare tech company founded in 2023 that develops AI-powered combination therapeutics for the world's toughest diseases. The company uses machine learning to discover multi-protein drug combinations that target multiple disease indications simultaneously. ### What products and services does Olio Labs offer? Olio Labs offers combination therapeutics developed through its AI-powered multi-protein drug discovery platform. The platform analyzes thousands of interacting proteins to create precise treatments that can target multiple proteins and body parts simultaneously. ### Who is Olio Labs for? Olio Labs targets patients suffering from the world's toughest diseases across multiple disease indications. Their combination therapeutics are designed to provide more precise treatment with lower doses and fewer side effects than current market drugs. ### When was Olio Labs founded? Olio Labs was founded in 2023 by Tom Roseberry and David Tingley. The company participated in Y Combinator's S23 batch. ### Where is Olio Labs based? Olio Labs is headquartered in San Francisco, California, United States. ### How much funding has Olio Labs raised? Olio Labs has raised $5M total over 2 rounds, including a $4.5M Series A in March 2025. The Series A was led by Boom Capital and Overwater Ventures, with participation from Pioneer Fund, SciFounders, Scrum Ventures, Y Combinator, and ZAKA. ### What key achievements has Olio Labs accomplished? Olio Labs has achieved drug combinations that beat current market drugs in both in vivo and in vitro testing for multiple disease indications. Their platform enables a 4x faster discovery process with 90% cost reduction compared to traditional methods. ### What technology does Olio Labs use? Olio Labs uses an AI and machine learning-powered platform that considers thousands of interacting proteins to discover optimal therapeutic combinations. This technology enables more precise treatments targeting multiple proteins and body parts simultaneously with lower doses and fewer side effects. ### How can I contact or learn more about Olio Labs? Based on the provided information, Olio Labs is located in San Francisco, CA. Specific contact details are not provided in the available information. ### What recent developments has Olio Labs announced? In March 2025, Olio Labs raised a $4.5M Series A led by Boom Capital and Overwater Ventures. The company has demonstrated that its combination therapeutics are beating current market drugs in testing across multiple disease indications. ## Tags healthtech, saas, ai-powered, north-america, b2b --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*